{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:37:16Z","timestamp":1791308236831,"version":"4.3.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Invasive aspergillosis is a severe fungal infection that affects multiple organ systems including the CNS and the lungs. Isavuconazole, a novel triazole antifungal agent, has demonstrated promising activity against Aspergillus spp. However, data on the penetration of isavuconazole into the CNS and ELF and intracellular accumulation remain limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>We conducted a prospective single-centre pharmacokinetic (PK) study in 12 healthy volunteers. Subjects received seven doses of 200 mg isavuconazole to achieve an assumed steady-state. After the first and final infusion, plasma sampling was conducted over 8 and 12 h, respectively. All subjects underwent one lumbar puncture and bronchoalveolar lavage, at either 2, 6 or 12 h post-infusion of the final dose. PBMCs were collected in six subjects from blood to determine intracellular isavuconazole concentrations at 6, 8 or 12 h. The AUC\/MIC was calculated for an MIC value of 1 mg\/L, which marks the EUCAST susceptibility breakpoint for Aspergillus fumigatus and Aspergillus flavus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>C max and AUC0-24h of isavuconazole in plasma under assumed steady-state conditions were 6.57\u200a\u00b1\u200a1.68 mg\/L (mean\u200a\u00b1\u200aSD) and 106\u200a\u00b1\u200a32.1 h\u00b7mg\/L, respectively. The average concentrations measured in CSF, ELF and in PBMCs were 0.07\u200a\u00b1\u200a0.03, 0.94\u200a\u00b1\u200a0.46 and 27.1\u200a\u00b1\u200a17.8 mg\/L, respectively. The AUC\/MIC in plasma, CSF, ELF and in PBMCs under steady-state conditions were 106\u200a\u00b1\u200a32.1, 1.68\u200a\u00b1\u200a0.72, 22.6\u200a\u00b1\u200a11.0 and 650\u200a\u00b1\u200a426 mg\u00b7h\/L, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Isavuconazole demonstrated moderate penetration into ELF, low penetrability into CSF and high accumulation in PBMCs. Current dosing regimens resulted in sufficient plasma exposure in all subjects to treat isolates with MICs\u200a\u2264\u200a1 mg\/L.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae088","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:09:30Z","timestamp":1711645770000},"page":"1169-1175","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-9036","authenticated-orcid":false,"given":"Felix","family":"Bergmann","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"},{"name":"Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"W\u00f6lfl-Duchek","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"},{"name":"Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-5878","authenticated-orcid":false,"given":"Anselm","family":"Jorda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9196-1936","authenticated-orcid":false,"given":"Valentin","family":"Al Jalali","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Leutzendorff","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"},{"name":"Department of Infectiology and Tropical Medicine, University Clinic of Internal Medicine I, Medical University Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1687-5296","authenticated-orcid":false,"given":"Maria","family":"Sanz-Codina","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gompelmann","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Trimmel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Eberl","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1709-4173","authenticated-orcid":false,"given":"Wisse","family":"Van Os","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris K","family":"Minichmayr","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Reiter","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna , Waehringer G\u00fcrtel 18-20, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stimpfl","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna , Waehringer G\u00fcrtel 18-20, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Idzko","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Internal Medicine II, Medical University of Vienna , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, 1090, Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"2024050202515408100_dkae088-B1","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Brahm","year":"2009","journal-title":"N Engl J Med"},{"key":"2024050202515408100_dkae088-B2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12281-023-00461-5","article-title":"Aspergillosis: an update on clinical spectrum, diagnostic schemes, and management","volume":"17","author":"Kanaujia","year":"2023","journal-title":"Curr Fungal Infect Rep"},{"key":"2024050202515408100_dkae088-B3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/jof9030315","article-title":"Pulmonary aspergillosis in critically ill COVID-19 patients admitted to the intensive care unit: a retrospective cohort study","volume":"9","author":"Bergmann","year":"2023","journal-title":"Journal of Fungi"},{"key":"2024050202515408100_dkae088-B4","doi-asserted-by":"crossref","first-page":"e00140-18","DOI":"10.1128\/CMR.00140-18","article-title":"Aspergillus fumigatus and aspergillosis in 2019","volume":"33","author":"Latg\u00e9","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2024050202515408100_dkae088-B5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/jof9060689","article-title":"Mortality in ICU patients with COVID-19-associated pulmonary aspergillosis","volume":"9","author":"Beltrame","year":"2023","journal-title":"J Fungi"},{"key":"2024050202515408100_dkae088-B6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.idc.2021.03.008","article-title":"Aspergillosis: epidemiology, diagnosis, and treatment","volume":"35","author":"Cadena","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"2024050202515408100_dkae088-B7","doi-asserted-by":"crossref","first-page":"e00399-19","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the treatment of invasive aspergillosis: from laboratory to bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11046-023-00727-z","article-title":"Treatment of invasive aspergillosis: how it\u2019s going, where it\u2019s heading","volume":"188","author":"Boyer","year":"2023","journal-title":"Mycopathologia"},{"key":"2024050202515408100_dkae088-B9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jiac.2022.10.010","article-title":"Efficacy and safety of isavuconazole against deep-seated mycoses: a phase 3, randomized, open-label study in Japan","volume":"29","author":"Kohno","year":"2023","journal-title":"J Infect Chemother"},{"key":"2024050202515408100_dkae088-B10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2024050202515408100_dkae088-B12","doi-asserted-by":"crossref","first-page":"e00524-19","DOI":"10.1128\/AAC.00524-19","article-title":"Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease","volume":"63","author":"Lee","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B13","volume-title":"Annex I Summary of Product Characteristics","author":"European Medicines Agency"},{"key":"2024050202515408100_dkae088-B14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1152\/jappl.1986.60.2.532","article-title":"Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution","volume":"60","author":"Rennard","year":"1986","journal-title":"J Appl Physiol"},{"key":"2024050202515408100_dkae088-B15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0022-1759(90)90432-U","article-title":"Mean cell volume of human blood leucocytes and resident and activated murine macrophages","volume":"129","author":"Nibbering","year":"1990","journal-title":"J Immunol Methods"},{"key":"2024050202515408100_dkae088-B16","volume-title":"Guideline on Bioanalytical Method Validation","author":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP)","year":"2011"},{"key":"2024050202515408100_dkae088-B17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024050202515408100_dkae088-B18","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.04907-14","article-title":"Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model","volume":"59","author":"Seyedmousavi","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B19","author":"Anon"},{"key":"2024050202515408100_dkae088-B20","doi-asserted-by":"crossref","first-page":"e0061323","DOI":"10.1128\/aac.00613-23","article-title":"Bronchopulmonary penetration of isavuconazole in lung transplant recipients","volume":"67","author":"Caballero-Bermejo","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B21","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bcp.13196","article-title":"Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs","volume":"83","author":"Motta","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2024050202515408100_dkae088-B22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jac\/dki075","article-title":"Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes","volume":"55","author":"Ballesta","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2024050202515408100_dkae088-B23","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.2147\/IJN.S298159","article-title":"Recent advances in macrophage-mediated drug delivery systems","volume":"16","author":"Liang","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"2024050202515408100_dkae088-B24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/mmy\/myab035","article-title":"Isavuconazole for treatment of refractory coccidioidal meningitis with concomitant cerebrospinal fluid and plasma therapeutic drug monitoring","volume":"59","author":"Davis","year":"2021","journal-title":"Med Mycol"},{"key":"2024050202515408100_dkae088-B25","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2024050202515408100_dkae088-B26","doi-asserted-by":"crossref","first-page":"e02474-18","DOI":"10.1128\/AAC.02474-18","article-title":"Isavuconazole diffusion in infected human brain","volume":"63","author":"Rouzaud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B27","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jac\/dkz050","article-title":"Isavuconazole brain penetration in cerebral aspergillosis","volume":"74","author":"Lamoth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024050202515408100_dkae088-B28","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B29","doi-asserted-by":"crossref","first-page":"e01643-18","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrobial Agents Chemotherapy"},{"key":"2024050202515408100_dkae088-B30","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B31","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00514-16","article-title":"Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study)","volume":"60","author":"Kovanda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B32","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/cpdd.1079","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of isavuconazonium sulfate in healthy adult Japanese subjects","volume":"11","author":"Shirae","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2024050202515408100_dkae088-B33","doi-asserted-by":"crossref","first-page":"e0044221","DOI":"10.1128\/AAC.00442-21","article-title":"Pharmacokinetics and bioequivalence of isavuconazole administered as isavuconazonium sulfate intravenous solution via nasogastric tube or orally in healthy subjects","volume":"65","author":"Desai","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202515408100_dkae088-B34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-017-2213-7","article-title":"Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics","volume":"73","author":"Townsend","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2024050202515408100_dkae088-B35","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1038\/s41598-021-85174-w","article-title":"Enteric reabsorption processes and their impact on drug pharmacokinetics","volume":"11","author":"Ibarra","year":"2021","journal-title":"Sci Rep"},{"key":"2024050202515408100_dkae088-B36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"2024050202515408100_dkae088-B37","volume-title":"Cresemba, Assessment Report","author":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP)","year":"2015"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/1169\/57368281\/dkae088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/1169\/57368281\/dkae088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T02:53:55Z","timestamp":1714618435000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/5\/1169\/7636755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,28]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae088","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,28]]}}}